Quantcast

Latest Pseudobulbar affect Stories

2014-08-05 16:27:40

ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2014. Quarterly Financial Highlights -- Total company net revenues of $28.6 million. -- Net NUEDEXTA® sales of $26.5 million. -- Cash, cash equivalents, and restricted investments of $87.6 million as of June 30, 2014. "We had a great quarter across all aspects of our business. I am delighted with...

2014-07-16 08:29:14

--Interim Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in Alzheimer's Disease/Dementia Population-- ALISO VIEJO, Calif., July 16, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced interim data from the phase IV PRISM II study showing that treatment with NUEDEXTA(®) substantially reduced symptoms of pseudobulbar affect (PBA) in patients with Alzheimer's disease/dementia. PBA is a distressing neurologic...

2014-06-30 20:22:37

ALISO VIEJO, Calif., June 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to pseudobulbar affect (PBA), a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate), the only FDA-approved product for the treatment of PBA, will be presented at the Alzheimer's Association International Conference (AAIC), being held at the Bela...

2014-05-30 08:25:39

ALISO VIEJO, Calif., May 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a distressing neurological condition characterized by uncontrollable laughing or crying, will be presented at the following conferences in June. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Joint Congress of European Neurology (EFNS-ENS), May 31 - June 3, 2014, Istanbul -- Burden of...

2014-05-06 16:32:33

ALISO VIEJO, Calif., May 6, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Quarterly Financial Highlights -- Total company net revenues of $26.9 million -- Net NUEDEXTA® sales of $24.4 million -- Cash, cash equivalents, and restricted investments of $56.5 million as of March 31, 2014. "We are extremely pleased...

2014-04-30 16:30:05

ALISO VIEJO, Calif., April 30, 2014, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company's patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications ('ANDAs') for generic versions of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the...

2014-04-28 08:27:50

New Data Demonstrate that NUEDEXTA® may Provide Early PBA Symptom Remission ALISO VIEJO, Calif., April 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and migraine development programs will be presented at the 66(th) American Academy of Neurology (AAN) Annual Meeting in Philadelphia. In addition, an article in the peer-reviewed publication, US Neurology,...

2014-03-19 08:30:22

Majority of Responding Veterans Surveyed Report Having PBA Symptoms, Adding an Extra Burden to Managing Life Post-TBI ALISO VIEJO, Calif., March 19, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the presentation of results from a first-of-its-kind study of pseudobulbar affect (PBA) symptoms in veterans with mild traumatic brain injury (TBI) conducted in collaboration with the Department of Veterans Affairs (VA) and Evidera. The study will be presented at the...

2014-02-05 16:27:36

ALISO VIEJO, Calif., Feb. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Quarterly Financial Highlights -- Total company net revenues of $26.7 million -- Gross and net NUEDEXTA® sales increased to $31.3 million and $23.3 million, respectively -- Cash, cash equivalents, and restricted investments of $46.5...

2014-01-13 08:27:28

ALISO VIEJO, Calif., Jan. 13, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary financial information (unaudited) for the quarter-ended December 31, 2013, in anticipation of the company's attendance at the J.P. Morgan 32(nd) Annual Healthcare Conference. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Based on preliminary financial information (unaudited) for the quarter-ended December 31, 2013, Avanir estimates: -- Total gross...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related